Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAF312 in Active Dermatomyositis: Double-Blind Randomized Dose-Ranging Phase 2 Trial
jRCT2080222539Phase 2
- Sponsor
- Novartis
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of siponimod in dermatomyositis (DM) (4 arms), sponsored by Novartis.
02
Drugs
siponimod
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on jRCT2080222539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222539.